by Mary Delaney
Daniel Polhamus is representing Metrum Research Group at the Alzheimer’s Association International Conference this week. If you missed our poster or handout, please download them here!
Daniel Polhamus is representing Metrum Research Group at the Alzheimer’s Association International Conference this week. If you missed our poster or handout, please download them here!
Topics: Neurodegenerative Diseases
Metrum Institute recently announced the open availability of pharmacometrics training lectures:
Topics: Metrum News
Though deemed “rare”, approximately 25—30 million Americans, and 300 million people worldwide, have been diagnosed with one of >6,800 known rare diseases. An estimated 50% of those affected are children. The prevalence of individual rare diseases can range from dozens in the US (progeria, hypophosphatasia, Niemann-Pick, for example), to thousands globally (such as, Crohn’s disease and cystic fibrosis). Although traditionally considered impractical for big pharma development, innovation and development of therapeutics for rare diseases have led to promising treatments for some diseases in recent decades. In the period of time from the passage of the Orphan Drug Act of 1983 until May 2010, the FDA approved 353 orphan drugs and granted orphan designations to 2,116 compounds. As of 2010, at 200 orphan diseases have become treatable (Armstrong). Still, rare diseases pose a critical unmet medical need.
Topics: Rare Disorders
Jonathan Sidi, Metrum Research Group
We are pleased to announce the release of the ggedit package on CRAN.
by Mary Delaney
Metrum Research Group was selected as one of the fastest growing technology companies in Connecticut at the 2012 Marcum Tech Top 40 awards ceremony at the Oakdale Theatre in Wallingford on September 27th.
Topics: Metrum News
Please take advantage of the content we provide here. Our goal is to help, encourge, and inspire you in your own work! If you have suggestions for blog topics, or would like to co-author a blog post with us, let us know!